This work was performed at Texas A&M University as a collaborative work within the Department of Small Animal Clinical Sciences, Department of Veterinary Physiology & Pharmacology (both part of the College of Veterinary Medicine), and the Center for Environmental, and Genetic Medicine in the Texas A&M Health Science Center.
Effect of Tolfenamic Acid on Canine Cancer Cell Proliferation, Specificity Protein (Sp) Transcription Factors, and Sp-Regulated Proteins in Canine Osteosarcoma, Mammary Carcinoma, and Melanoma Cells
Article first published online: 27 APR 2012
Copyright © 2012 by the American College of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine
Volume 26, Issue 4, pages 977–986, July-August 2012
How to Cite
Wilson, H., Chadalapaka, G., Jutooru, I., Sheppard, S., Pfent, C. and Safe, S. (2012), Effect of Tolfenamic Acid on Canine Cancer Cell Proliferation, Specificity Protein (Sp) Transcription Factors, and Sp-Regulated Proteins in Canine Osteosarcoma, Mammary Carcinoma, and Melanoma Cells. Journal of Veterinary Internal Medicine, 26: 977–986. doi: 10.1111/j.1939-1676.2012.00931.x
Data from this project were presented at the 30th annual Veterinary Cancer Society Meeting, October 31, 2010 in San Diego, California
- Issue published online: 13 JUL 2012
- Article first published online: 27 APR 2012
- Manuscript Accepted: 10 MAR 2012
- Manuscript Revised: 2 FEB 2012
- Manuscript Received: 10 DEC 2010
- Mammary carcinoma;
Tolfenamic acid (TA) is an NSAID currently under investigation as an anticancer agent in humans. TA induces proteosome-dependent degradation of transcription factors Sp 1, 3, and 4. These proteins are known to be overexpressed in many human cancers.
To evaluate the protein expression of Sps in canine tissue, and efficacy of TA against several canine tumor cell lines.
Six canine cell lines (2 osteosarcoma, 2 mammary carcinoma, 2 melanoma) were evaluated. Protein levels of Sp 1–4 and their downstream targets were evaluated using Western Blots. Cell survival and TUNEL assays were performed on cell lines, and Sp1 expression was evaluated on histologic samples from archived canine cases.
Six immortalized canine cancer cell lines derived from dogs were used. Archived tissue samples were also used.
Sps were highly expressed in all 6 cell lines and variably expressed in histologic tissues. TA decreased expression of Sps 1–4 in all cell lines. All of the downstream targets of Sps were inhibited in the cell lines. Variable Sp1 expression was identified in all histologic samples examined. TA significantly inhibited cell survival in all cell lines in a dose dependant fashion. The number of cells undergoing apoptosis was significantly increased (P < .05) in all cell lines after exposure to TA in a dose-dependent fashion.
Conclusions, and Clinical Importance
Tolfenamic acid is a potential anticancer NSAID and further investigation is needed to determine its usefulness in a clinical setting.